## Silvia Amoretti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/486704/publications.pdf

Version: 2024-02-01

64 papers

1,742 citations

393982 19 h-index 301761 39 g-index

67 all docs

67
docs citations

67 times ranked

2243 citing authors

#	Article	IF	CITATIONS
1	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry, the, 2019, 6, 427-436.	3.7	528
2	Resilience and mental health during the COVID-19 pandemic. Journal of Affective Disorders, 2021, 283, 156-164.	2.0	98
3	The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. European Neuropsychopharmacology, 2016, 26, 1638-1648.	0.3	89
4	Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0. Frontiers in Psychiatry, 2018, 9, 641.	1.3	79
5	Effects of the COVID-19 pandemic and lockdown in Spain: comparison between community controls and patients with a psychiatric disorder. Preliminary results from the BRIS-MHC STUDY Journal of Affective Disorders, 2021, 281, 13-23.	2.0	70
6	Cognitive reserve as an outcome predictor: firstâ€episode affective versus nonâ€affective psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 441-455.	2.2	66
7	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research, 2017, 189, 84-90.	1.1	49
8	Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis. Schizophrenia Bulletin, 2019, 45, 846-858.	2.3	41
9	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. Psychological Medicine, 2018, 48, 2247-2256.	2.7	40
10	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences, 2020, 29, e182.	1.8	36
11	Examining Gene–Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. Schizophrenia Bulletin, 2020, 46, 1019-1025.	2.3	32
12	Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 699-711.	1.8	31
13	Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability. Journal of Clinical Medicine, 2019, 8, 586.	1.0	31
14	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. Psychological Medicine, 2020, 50, 2702-2710.	2.7	31
15	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. International Journal of Neuropsychopharmacology, 2016, 19, pyv121.	1.0	29
16	Persistent Negative Symptoms in First-Episode Psychosis. Journal of Clinical Psychiatry, 2017, 78, 1414-1422.	1.1	28
17	Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. European Psychiatry, 2020, 63, e71.	0.1	27
18	Affective versus non-affective first episode psychoses: A longitudinal study. Journal of Affective Disorders, 2018, 238, 297-304.	2.0	26

#	Article	IF	Citations
19	Risk of cancer in bipolar disorder and the potential role of lithium: International collaborative systematic review and meta-analyses. Neuroscience and Biobehavioral Reviews, 2021, 126, 529-541.	2.9	23
20	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	4.1	23
21	The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds. European Neuropsychopharmacology, 2021, 47, 98-111.	0.3	21
22	Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique. European Neuropsychopharmacology, 2021, 47, 112-129.	0.3	20
23	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Psychiatry, 2021, 64, e25.	0.1	18
24	The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses. Psychological Medicine, 2022, 52, 526-537.	2.7	17
25	Trajectories of suicidal ideation after firstâ€episode psychosis: a growth mixture modeling approach. Acta Psychiatrica Scandinavica, 2021, 143, 418-433.	2.2	17
26	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. European Neuropsychopharmacology, 2019, 29, 786-794.	0.3	16
27	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophrenia Research, 2022, 243, 32-42.	1.1	15
28	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. Schizophrenia Bulletin, 2020, 46, 517-529.	2.3	14
29	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	2.7	14
30	Cognitive reserve in mental disorders. European Neuropsychopharmacology, 2021, 49, 113-115.	0.3	14
31	Exploring Risk and Resilient Profiles for Functional Impairment and Baseline Predictors in a 2-Year Follow-Up First-Episode Psychosis Cohort Using Latent Class Growth Analysis. Journal of Clinical Medicine, 2021, 10, 73.	1.0	14
32	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 164-176.	1.0	13
33	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.  Translational Psychiatry, 2021, 11, 423.	2.4	12
34	The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years. European Neuropsychopharmacology, 2021, 49, 54-68.	0.3	12
35	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. Schizophrenia Bulletin, 2020, 46, 846-856.	2.3	10
36	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine, 2022, 52, 1777-1783.	2.7	10

3

#	Article	IF	CITATIONS
37	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. Journal of Clinical Medicine, 2021, 10, 2474.	1.0	10
38	Cognitive clusters in first-episode psychosis. Schizophrenia Research, 2021, 237, 31-39.	1.1	10
39	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	2.5	10
40	Spatial Suppression and Sensitivity for Motion in Schizophrenia. Schizophrenia Bulletin Open, 2020, 1, .	0.9	9
41	Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis. Schizophrenia Research, 2020, 223, 345-352.	1.1	8
42	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. Psychopharmacology, 2021, 238, 665-676.	1.5	8
43	Food craving and consumption evolution in patients starting treatment with clozapine. Psychopharmacology, 2019, 236, 3317-3327.	1.5	7
44	Self-reported neurocognitive symptoms during COVID-19 lockdown and its associated factors in a sample of psychiatric patients. Results from the BRIS-MHC study. European Neuropsychopharmacology, 2021, 53, 7-18.	0.3	7
45	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. Schizophrenia Research, 2020, 218, 292-294.	1.1	6
46	Sex differences in neurocognitive and psychosocial functioning in bipolar disorder. Journal of Affective Disorders, 2022, 296, 208-215.	2.0	6
47	Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment. Journal of Clinical Psychopharmacology, 2022, 42, 75-80.	0.7	6
48	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. Schizophrenia Research, 2021, 236, 19-28.	1.1	5
49	The role of genetics in cognitive remediation in schizophrenia: A systematic review. Schizophrenia Research: Cognition, 2020, 19, 100146.	0.7	4
50	The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory. Psychological Medicine, 2021, 51, 2044-2053.	2.7	4
51	Is the effect of cognitive reserve in longitudinal outcomes in first-episode psychoses dependent on the use of cannabis?. Journal of Affective Disorders, 2022, 302, 83-93.	2.0	4
52	Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. Acta Psychiatrica Scandinavica, 2022, 146, 36-50.	2.2	4
53	Shaped before birth: Obstetric complications identify a more severe clinical phenotype among patients presenting a first affective or non-affective episode of psychosis. Journal of Psychiatric Research, 2022, 151, 461-468.	1.5	4
54	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 164-176.	0.2	3

#	Article	IF	CITATIONS
55	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Revista De PsiquiatrÃa Y Salud Mental, 2021, , .	1.0	3
56	Cortical thinning over two years after first-episode psychosis depends on age of onset. NPJ Schizophrenia, 2022, 8, 20.	2.0	3
57	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. Psychological Medicine, 2023, 53, 4634-4647.	2.7	3
58	Emotional intelligence: a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I. Psychological Medicine, 2023, 53, 3065-3076.	2.7	2
59	Sex and substance use in first episode psychosis: Impact on clinical symptoms, psychosocial functioning and cognitive performance. Revista De PsiquiatrÃa Y Salud Mental, 2022, , .	1.0	1
60	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S318-S318.	2.3	0
61	M60. EARLY VERSUS DELAYED PRESCRIPTION OF CLOZAPINE AND THE COGNITIVE PERFORMANCE ON SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S157-S158.	2.3	0
62	M123. EPISODIC VERBAL MEMORY DEFICIT IN SCHIZOPHRENIA: A MARKER OF PROGRESSION OF DISEASE OR DIFFERENT NEURODEVELOPMENTAL PATHWAYS FROM THE ONSET?. Schizophrenia Bulletin, 2020, 46, S182-S182.	2.3	0
63	M176. INTESTINAL PERMEABILITY AND LOW-GRADE CHRONIC INFLAMMATION IN SCHIZOPHRENIA: DO THEY INFLUENCE COGNITION AND COGNITIVE RESERVE?. Schizophrenia Bulletin, 2020, 46, S203-S204.	2.3	O

Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT
Val158Met polymorphism in first episode psychosis. Revista De PsiquiatrÃa Y Salud Mental (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5